Eli Lilly (LLY) is broadening access to its weight-loss medication, Zepbound, by partnering with telehealth platform Ro. This collaboration allows patients to obtain single-dose vials of Zepbound through Lilly’s direct-to-consumer platform, LillyDirect. Ro is the first telehealth platform to integrate with LillyDirect, offering a new avenue for patients seeking FDA-approved weight management solutions.
Table Content:
Expanding Access to Zepbound: A Strategic Move
This partnership signifies a significant step in Lilly’s strategy to expand access to Zepbound while addressing previous supply challenges. By leveraging Ro’s telehealth infrastructure, Lilly can reach a wider patient population and offer a more affordable option with single-dose vials. This move also allows Lilly to compete more effectively with compounded versions of tirzepatide, the active ingredient in Zepbound.
Patrik Jonsson, executive vice president and president of Lilly Cardiometabolic Health, emphasized the importance of providing broader availability of rigorously tested and FDA-approved obesity treatment. The collaboration with Ro reinforces this commitment by offering a convenient and cost-effective option for patients seeking access to Zepbound.
Overcoming Supply Challenges and Competing with Compounded Alternatives
The introduction of single-dose vials addresses prior production constraints associated with auto-injectors, which had led to supply shortages. While the FDA has declared these shortages over, the decision regarding compounded GLP-1s remains pending. Lilly’s partnership with Ro offers a reliable alternative to compounded versions of tirzepatide.
Ro CEO Zach Reitano highlighted the speed and efficiency with which the partnership was established. He noted that the integration with LillyDirect took place just over 100 days after the launch of the single-dose vial option.
Addressing Patient Needs and Providing Support
While administering injections from vials might initially seem challenging for some patients, Reitano explained that many individuals with diabetes or experience with fertility treatments are already familiar with needles. Ro provides comprehensive support through its website, offering detailed instructions and videos on how to administer the injections. The popularity of these resources demonstrates Ro’s commitment to patient education and support.
Conclusion: A Positive Step Towards Broader Access
The partnership between Eli Lilly and Ro signifies a significant development in expanding access to Zepbound. By leveraging Ro’s telehealth platform and LillyDirect, patients gain a convenient and affordable way to obtain this FDA-approved weight-loss medication. This strategic move addresses previous supply challenges, offers a reliable alternative to compounded drugs, and underscores Lilly’s commitment to providing innovative solutions for patients seeking effective weight management options.
